XDx is a novel molecular diagnostics company whose mission is to improve patient care by developing molecular diagnostics that translate an individual’s immune status into clinically actionable information. The Company has developed an accurate blood-based diagnostic test to detect rejection in heart transplant patients. The test measures the level of gene expression for the set of genes most closely involved in the immune response of heart transplant tissue rejection. The test will partially replace biopsies, which are more costly, painful, invasive/risky, subjective, non-quantitative and slower to detect organ rejection. XDx is developing similar tests for other organ transplants such as lung transplants, as well as tests for autoimmune disorders. In addition to DBL Partners, investors include Kleiner Perkins Caufield and Byers, Texas Pacific Group, New Leaf Venture Partners, Burrill and Company, Integral Capital Partners, Intel Capital Partners and Duff Ackerman and Goodrich.
Location: United States, California, Brisbane
Total raised: $18.5M
Investors 3
| Date | Name | Website |
| - | DBL Partne... | dbl.vc |
| 08.05.2021 | DBL Partne... | dblpartner... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 31.01.2011 | - | $12.5M | - |
| 13.07.2010 | - | $6M | - |
Mentions in press and media 7
| Date | Title | Description | Source |
| 27.09.2012 | The Next Big Niche? Emerging Med-Tech for Transplant. | As an advisor to emerging med tech companies, I am always on the lookout for attractive niche market... | medcitynew... |
| 31.01.2011 | XDx Receives $12.5M Loan Facility from GE Capital, Healthcar... | XDx, Inc., a Brisbane, California-based molecular diagnostics company, has received a $12.5m senior ... | finsmes.co... |
| 13.07.2010 | XDx Secures $6M Debt | Share Share on Facebook Share on Twitter LinkedIn Email Reprints XDx, the Brisbane, CA-based develo... | xconomy.co... |
| 16.06.2008 | Gene expression diagnostic company XDx raises $35.4M more | XDx, the startup behind a test measuring gene activity in the blood, is raising an additional $35.4 ... | venturebea... |
| 27.10.2007 | Gene-expression tester XDx marks the spot with an $86M IPO b... | See our story on this Brisbane, Calif., genomic-diagnostic firm at VentureBeat Life Sciences. Ventu... | venturebea... |
| 25.10.2007 | XDx marks a spot: An $86M IPO for gene-expression diagnostic... | (UPDATED: See below.) When XDx yesterday filed to raise up to $86.3 million in an IPO, the Brisbane... | venturebea... |
| - | The Next Big Niche? Emerging Med-Tech for Transplant. | As an advisor to emerging med tech companies, I am always on the lookout for attractive niche market... | medcitynew... |